| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e0858af88667d9438916a278100be78 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 |
| filingDate |
2019-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04eb81ba7f62536017482ef0aa3fdb3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50fa7e2f35f1566922d09da6c91af8a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e82bc1dedbae208898b2215f796abfc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8f525465d7b4ed66ad77a89d3b6bbc2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af75a45a71198bebebc03ac25b31fd7c |
| publicationDate |
2021-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20210013145-A |
| titleOfInvention |
Heterocyclic compounds as kinase inhibitors, compositions containing heterocyclic compounds, and methods of using the same |
| abstract |
[Formula I] The present invention relates to a compound of formula (I) and/or a stereoisomer, tautomer, stable isotope or pharmaceutically acceptable salt thereof; And therapeutic uses of these compounds. They are potentially useful kinase inhibitors in the treatment of treatable diseases such as cancer. The invention also relates to compounds of formula (I) and/or stereoisomers, tautomers, stable isotopes or pharmaceutically acceptable salts thereof; And it discloses a pharmaceutical composition comprising a pharmaceutically acceptable carrier. |
| priorityDate |
2018-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |